Mixed CARE-MS I data – Good for BIIB!
Sanofi/GENZ’s Lemtrada (alemtuzumab, PhIII, RRMS) met the primary end point (reduction in relapse rate), but secondary endpoint- time to six month sustained accumulation of disability (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players in the MS field? Please read our report, released on 11th July, 2011, titled – “Mixed CARE-MS I data – Good for BIIB!”
COMPANIES MENTIONED
BIOGEN IDEC
BIOGEN IDEC
